4-肼基丁烷-1-醇 | 84157-94-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-肼基丁烷-1-醇
• 英文名称: 4-hydrazinobutan-1-ol
• 英文别名: 4-Hydrazinylbutan-1-ol
• CAS: 84157-94-8
• 化学式: C₄H₁₂N₂O
• mdl: MFCD14583056
• 分子量: 104.152
• InChiKey: FQKGONKJQQBWKD-UHFFFAOYSA-N

物化性质

• 沸点：
  118 °C(Press: 2.0 Torr)
• 密度：
  0.996±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  7
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  邻苯甲酰苯甲酸 、 4-肼基丁烷-1-醇 以 乙醇 为溶剂， 反应 1.0h， 以97%的产率得到2-(4-hydroxybutyl)-4-phenylphthalazin-1(2H)-one
  参考文献：
  名称：

  溴烷基邻苯二氮酮和异构的恶唑啉鎓盐作为中间体和合成子

  摘要：

  2（ω-哌啶子基烷基）酞嗪-1（2H）-1可以由2-羟基烷基化合物制备，既可以是开链的2-溴烷基衍生物，也可以是它们的环状异构体。溴烷基化合物的取代反应可以通过极性溶剂和肼基羰基部分的邻近基团效应来辅助。亲核分子在三环中间体中的稠合的恶唑啉鎓盐环上以开环键合到与氧键合的饱和碳上，攻击环上的稠合恶唑啉鎓环。仅在具有恶唑啉鎓和强吸电子am基部分的四环双阳离子中发现将哌啶加成至不饱和亚氨基-碳。

  DOI：

  10.1016/s0040-4020(01)89500-4
• 作为产物：
  描述：

  4-氯丁醇 在 一水合肼 作用下， 反应 48.0h， 生成 4-肼基丁烷-1-醇
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
  [FR] PYRAZOLOAZÉPIN-4-ONES SUBSTITUÉES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE

  摘要：

  本发明涉及具有磷酸二酯酶抑制活性的新型取代吡唑啉-4-酮化合物，以及它们作为治疗炎症性疾病和症状的治疗剂的用途。

  公开号：

  WO2018108230A1

文献信息

• [EN] SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] PYRAZOLOAZÉPIN-4-ONES SUBSTITUÉES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE
  申请人：LEO PHARMA AS

  公开号：WO2018108910A1

  公开（公告）日：2018-06-21

  The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents the treatment of inflammatory diseases and conditions.

  本发明涉及具有磷酸二酯酶抑制活性的新型取代吡唑烯并-4-酮化合物，以及它们作为治疗炎症性疾病和症状的治疗剂的用途。
• Alcohol derivatives
  申请人：Imperial Chemical Industries PLC

  公开号：US04451463A1

  公开（公告）日：1984-05-29

  This invention relates to alcohol derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I: ##STR1## in which R.sup.1 and R.sup.2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R.sup.1 and R.sup.2 is halogen-substituted, or R.sup.2 is hydrogen and R.sup.1 is R.sup.5 --E--W-- in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyl, E is O, S, SO, SO.sub.2 or NR.sup.6 in which R.sup.6 is H or 1-6C alkyl, R.sup.5 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R.sup.5 and R.sup.6 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring, or R.sup.2 is hydrogen and R.sup.1 is hydrogen or 1-10C alkyl, 3-8C cycloalkyl, 4-14C cycloalkylalkyl, 3-6C alkenyl, 3-6C alkynyl, 1-6C alkanoyl, 6-10C aryl, 7-11C arylalkyl or 7-11C aroyl, the aryl, arylalkyl and aroyl radicals being optionally substituted, ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene or a 1-8C alkylene into which is optionally inserted one or two groups; D is oxygen or sulphur; R.sup.3, R.sup.4 and R.sup.5 are hydrogen or a variety of radicals described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  本发明涉及酒精衍生物，它们是组胺H-2拮抗剂并且抑制胃酸分泌。根据本发明，提供了化学式I的胍衍生物：其中R.sup.1和R.sup.2，相同或不同，是氢或1-10C烷基，3-8C环烷基或4-14C环烷基烷基，每个烷基，环烷基或环烷基烷基可选择携带一个或多个F、Cl或Br原子，前提是R.sup.1和R.sup.2中的一个是卤素取代的，或者R.sup.2是氢而R.sup.1是R.sup.5--E--W--，其中W是可选择通过1或2个1-4C烷基取代的2-6C烷基，E是O、S、SO、SO.sub.2或NR.sup.6，其中R.sup.6是H或1-6C烷基，R.sup.5是H或1-6C烷基，可选择通过1或2个1-4C烷基取代，或者R.sup.5和R.sup.6结合形成吡咯烷、哌啶、吗啉、哌嗪或N-甲基哌嗪环，或者R.sup.2是氢而R.sup.1是氢或1-10C烷基，3-8C环烷基，4-14C环烷基烷基，3-6C烯基，3-6C炔基，1-6C醇酰基，6-10C芳基，7-11C芳基烷基或7-11C酰基，芳基、芳基烷基和酰基基团可选择取代，环X是规范中定义的杂环，A是苯基或5-7C环烷基或可选择插入一到两个基团的1-8C烷基，D是氧或硫，R.sup.3、R.sup.4和R.sup.5是氢或规范中描述的多种基团，以及其药用可接受酸盐。同时描述了制造工艺和药用组合物。
• Bicyclic guanidines
  申请人：Imperial Chemical Industries PLC

  公开号：US04463005A1

  公开（公告）日：1984-07-31

  The invention relates to bicyclic derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I: ##STR1## in which R.sup.1 and R.sup.2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R.sup.1 and R.sup.2 is halogen substituted, or R.sup.2 is hydrogen and R.sup.1 is R.sup.3 -E-W in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O, S, SO, SO.sub.2 or NR.sup.4 in which R.sup.4 is H or 1-6C alkyl, R.sup.3 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R.sup.3 and R.sup.4 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring, or R.sup.2 is H and R.sup.1 is H, 1-10C alkyl, 3-8C cycloalkyl, 4-14C cycloalkylalkyl, 3-6C alkenyl, 3-6C alkynyl, 1-6C alkanoyl, 6-10C aryl, 7-11C aralkyl or 7-11C aroyl; ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene, or a 1-8 C alkylene into which is optionally inserted one or two groups; ring Y is a heterocyclic ring described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  该发明涉及一类双环衍生物，它们是组织胺H-2受体拮抗剂，并且能够抑制胃酸分泌。根据该发明，提供了一种具有以下式I的胍基衍生物：##STR1## 其中R.sup.1和R.sup.2，相同或不同，为氢或1-10C烷基，3-8C环烷基或4-14C环烷基烷基，每个烷基、环烷基或环烷基烷基可选地携带一个或多个F、Cl或Br原子，前提是R.sup.1和R.sup.2中的一个被卤素取代，或者R.sup.2为氢且R.sup.1为R.sup.3-E-W，其中W为2-6C烷基烯，可选地取代1或2个1-4C烷基，E为O、S、SO、SO.sub.2或NR.sup.4，其中R.sup.4为H或1-6C烷基，R.sup.3为H或1-6C烷基，可选地取代1或2个1-4C烷基，或者R.sup.3和R.sup.4连接形成吡咯烷、哌啶、吗啉、哌嗪或N-甲基哌嗪环，或者R.sup.2为H且R.sup.1为H、1-10C烷基、3-8C环烷基、4-14C环烷基烷基、3-6C烯基、3-6C炔基、1-6C烷酰基、6-10C芳基、7-11C芳基烷基或7-11C芳酰基；环X为规范中定义的杂环；A为苯环或5-7C环烷基，或者可选地插入一到两个基团的1-8C烷基；环Y为规范中描述的杂环；以及其药用可接受的酸盐。还描述了制药过程和制药组合物。
• Michael addition of<i>N</i>-isobutylidene-<i>t</i>-butylamine to dimethyl methoxymethylenemalonate and a new synthesis of some fused pyrazole derivatives from the adduct
  作者：Kunio Ito、Shogo Ihara、Shingo Miyajima

  DOI：10.1002/jhet.5570300613

  日期：1993.12

  N-Isobutylidenemethylamine reacted with dimethyl methoxymethylenemalonate to afford the N-alkylation product 3a exclusively. Exchanging the N-substituent of the Schiff's base from methyl to t-butyl altered the course of the reaction, allowing Michael addition to take place predominantly. The Michael adduct 4c on reaction with hydrazinoalkanols 6a,b, 6c,d and 6e gave tetrahydropyrazolo[5,1-b]oxazoles

  N-异丁叉亚甲基胺与甲氧基亚甲基丙二酸二甲酯反应，仅得到N-烷基化产物3a。将席夫氏碱的N-取代基从甲基交换为叔丁基会改变反应过程，从而使Michael加成反应主要发生。与肼基链烷醇6a，b，6c，d和6e反应的迈克尔加合物4c得到四氢吡唑并[5,1 - b ]恶唑9a，b，四氢吡唑并[5,1- b ] [1,3]恶嗪9c，d和六氢吡唑并[5,1- b ] [1,3]奥氮平9e， 分别。
• Preparation of heterocyclic dications from substituted phthalazinones
  作者：A. Csámpai、K. Körmendy、T. Sohár、J. Császár、F. Ruff

  DOI：10.1016/s0040-4020(01)87877-7

  日期：1990.1

  avoided the formation of seven-membered ring with either isomerisation or degradation involving cleavage of C-N bond assisted by neighbouring group participation of the hydroxyl group. The sequence of ring closures depends on the ring substituents and the lengths of side chains. The reaction mechanism is also influenced by the site of the protonation. The structures of the new tetracycles were proved

  使用高氯酸将2-（ω-羟基烷基）-4-（ω）'-羟基烷基-氨基）酞嗪酮及其6,7-二甲氧基衍生物转化为同时包含亚氨基醚和am部分的四环阳离子。2-（4-羟基） utyl）链避免了七元环的形成，无论是异构化还是降解都涉及羟基相邻基团的参与辅助CN键的裂解。闭环的顺序取决于环取代基和侧链的长度。反应机理也受质子化位点的影响。新的四环化合物的结构通过1 H-和13 C-nmr光谱证明。